Optical Coherence Tomography Gains Regulatory Traction in Pharma Filings
Recent regulatory updates have formally recognized Optical Coherence Tomography (OCT) as a valid analytical technique for pharmaceutical filings. This development promises to streamline drug development processes and offers significant implications for pharmaceutical business development teams, investors, and analysts.
Quick Answer
Recent regulatory updates have formally recognized Optical Coherence Tomography (OCT) as a valid analytical technique for pharmaceutical filings. This development promises to streamline drug development processes and offers significant implications for pharmaceutical business development teams, investors, and analysts.
Key Questions
- What types of pharmaceutical products benefit most from OCT?
- Does regulatory recognition mean OCT can replace dissolution testing?
- Which regulatory agencies have formally accepted OCT?
- How quickly should companies expect to see ROI from OCT adoption?
Contents7 sections
Optical Coherence Tomography Gains Regulatory Traction in Pharma
Recent regulatory updates have formally recognized Optical Coherence Tomography (OCT) as a valid analytical technique for pharmaceutical filings. This development promises to streamline drug development processes and offers significant implications for pharmaceutical business development teams, investors, and analysts.
What Are the Key Takeaways for Pharma Stakeholders?
- OCT now sits within formal regulatory frameworks as an accepted analytical method, lowering adoption risk for manufacturers and creating a clear compliance pathway for faster approval cycles.
- Early adopters of OCT can shorten analytical timelines and reduce development costs, making them more attractive M&A targets or licensing partners, particularly for mid-cap firms looking to differentiate quality control.
- BD and regulatory teams must revise internal workflows and due diligence checklists to account for OCT's new standing or risk overlooking a key efficiency lever in partnerships.
- Investors and analysts should monitor companies that have publicly integrated OCT into manufacturing or process development; these firms may file more efficiently and secure stronger regulatory compliance profiles.
How Did OCT Earn Regulatory Recognition?
The regulatory acceptance of OCT did not happen overnight. A comprehensive review published in Frontiers in Medicine in October 2023 consolidated years of research and industry experience, presenting an integrated perspective on how OCT can be developed, implemented, and evaluated within the pharmaceutical regulatory framework. That work, also hosted by the National Library of Medicine, served as a key reference for both the FDA and EMA as they updated their guidelines on analytical methods. The recognition formalizes what many quality teams had already begun doing informally—using OCT for real-time, non-destructive analysis of coating thickness, tablet structure, and injectable particle counts.
The same Frontiers article details how OCT bridges a gap that traditional analytical techniques leave open: it offers micron-resolution imaging without sample destruction, enabling manufacturers to test finished products in-line rather than pulling samples for off-line lab work. This capability aligns directly with the FDA's ongoing push for process analytical technology (PAT), formalized in its PAT guidance, which encourages real-time quality assurance. The EMA has also incorporated OCT into the scope of its quality-by-design framework, particularly under ICH Q8(R2), providing a clear path for sponsors to use OCT in design space development.
How Will OCT Impact Pharma Business Development and Investment?
The shift matters most to BD teams evaluating potential partners. A company that has already validated OCT for its solid-dose or biologic pipeline can offer shorter technology transfer timelines and fewer regulatory surprises. In licensing talks, that efficiency translates into higher valuations—buyers pay a premium for de-risked manufacturing. Conversely, a target that still relies solely on traditional dissolution testing and HPLC may face longer integration timelines, which BD teams should factor into deal terms.
For investors, OCT adoption is a leading indicator of operational maturity. Public companies that disclose OCT integration in their annual reports or regulatory filings signal that they are investing in advanced quality systems. Analysts can track these disclosures as a proxy for a firm’s readiness to handle complex drug profiles—especially for long-acting injectables, transdermals, and ophthalmic products where OCT delivers critical film-thickness or particle-size data. The regulatory nod effectively removes a barrier to technology transfer, making OCT-capable manufacturers more attractive for contract development and manufacturing organization (CDMO) partnerships.
M&A activity in the CDMO space has already shown a premium for companies with advanced analytical capabilities. Deal teams are likely to add OCT capability checks to their standard due diligence templates. Smaller diagnostic firms that hold OCT intellectual property could become acquisition targets for larger pharma companies looking to in-source the expertise.
What Should Regulatory Teams Change Now?
Regulatory affairs departments should immediately begin mapping their existing analytical methods against OCT’s capabilities. For products already in development, a comparability protocol may be needed to substitute an existing destructive test for an OCT-based non-destructive one. The FDA’s PAT framework provides a pathway for such substitutions, but the burden of proof lies with the sponsor to show that OCT yields equivalent or superior results. Teams should prepare a data package that includes validation runs across at least three batches, using the specific OCT hardware configuration they intend to deploy in commercial manufacturing.
Training is another critical step. Current staff may be unfamiliar with OCT’s data outputs—typically cross-sectional interferograms—and how to interpret them against pharmacopeial acceptance criteria. Regulatory teams should budget for vendor-provided training sessions and consider forming internal working groups to establish standard operating procedures. The EMA’s quality guidelines, particularly ICH Q8(R2), now offer scope for embedding OCT in the design space approach, which can streamline post-approval changes.
Frequently Asked Questions
What types of pharmaceutical products benefit most from OCT?
OCT is especially useful for coated tablets, transdermal patches, ophthalmic injectables, and other dosage forms where layer thickness, integrity, or particle distribution must be maintained. Its non-destructive, real-time nature makes it ideal for continuous manufacturing lines where traditional batch sampling would interrupt flow.
Does regulatory recognition mean OCT can replace dissolution testing?
No. OCT is a complementary technique, not a replacement for pharmacopeial tests like dissolution or content uniformity. However, it can reduce the frequency of those tests by providing in-process assurance that the product is within spec, allowing manufacturers to shift from end-product testing to real-time release.
Which regulatory agencies have formally accepted OCT?
Both the FDA and the EMA have incorporated references to OCT in their latest guidance documents on process analytical technology and quality by design. The specific update that gained industry attention was the October 2023 review published in Frontiers in Medicine, which the agencies cited as a foundational reference during advisory meetings with industry groups.
How quickly should companies expect to see ROI from OCT adoption?
Early adopters report recouping hardware and validation costs within 12–18 months through reduced lab analysis time, fewer rejected batches, and faster regulatory submissions. For high-volume solid-dose products, the savings are amplified because OCT can inspect every unit in line rather than a statistical sample.
Related coverage
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
